Skip to main content

Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading up 6 points (0.0%) at 17,798 as of Tuesday, Nov. 24, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,309 issues advancing vs. 1,608 declining with 176 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include

Shire

(

SHPG

), down 1.2%,

Sanofi

(

SNY

), down 1.0% and

AstraZeneca

(

TheStreet Recommends

AZN

), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Celgene

(

CELG

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Celgene is down $1.48 (-1.3%) to $112.12 on light volume. Thus far, 1.1 million shares of Celgene exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $111.93-$113.65 after having opened the day at $113.07 as compared to the previous trading day's close of $113.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $89.2 billion and is part of the health care sector. Shares are up 1.6% year-to-date as of the close of trading on Monday. Currently there are 13 analysts that rate Celgene a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Merck

(

MRK

) is down $0.72 (-1.3%) to $53.28 on light volume. Thus far, 3.6 million shares of Merck exchanged hands as compared to its average daily volume of 13.2 million shares. The stock has ranged in price between $53.10-$53.68 after having opened the day at $53.56 as compared to the previous trading day's close of $54.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $151.1 billion and is part of the health care sector. Shares are down 4.9% year-to-date as of the close of trading on Monday. Currently there are 7 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $0.63 (-0.6%) to $105.73 on light volume. Thus far, 2.4 million shares of Gilead exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $105.50-$106.30 after having opened the day at $105.75 as compared to the previous trading day's close of $106.36.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $153.5 billion and is part of the health care sector. Shares are up 12.8% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).